## IN THE CLAIMS:

Please amend claims 1-3, 5-8, 22-24 and 26, cancel claims 4, 11-21, 25, 30 and 31, and add new claims 32-49.

- (Currently amended) An isolated nucleic acid molecule that encodes protein comprising at least one epitope of membrane IgE and at least one nonIgE helper T cell epitope, and being free of epitopes of serum IgE.
- (Currently amended) The nucleic acid molecule of claim 1 wherein said protein is comprises membrane IgE or fragment thereof.
- (Currently amended) The nucleic acid molecule of claim 2 wherein said protein is comprises membrane IgE.
- 4. (Canceled)
- 5. (Currently amended) The nucleic acid molecule of claim 4 1 wherein the coding sequence encoding of the at least one non-IgE. helper T cell epitope encodes tetanus toxoid Th epitope.
- 6. (Currently amended) The nucleic acid molecule of claim 2 1 wherein said nucleic acid molecule is a plasmid.
- (Currently amended) The nucleic acid molecule of claim 2 1 wherein said nucleic acid molecule is incorporated in a viral vector or a bacterial cell.

- 8. (Currently amended) A vaccine composition comprising a nucleic acid molecule of elaim 1 that encodes protein comprising at least one epitope of membrane IgE and being free of epitopes of serum IgE, and a pharmaceutically acceptable carrier or diluent.
- 9. (Currently amended) A method of treating an individual who has been identified as being susceptible to an IgE mediated allergic disease or condition comprising the step of administering to such an individual a prophylactically effective amount of a vaccine of claim 8.
- 10. (Currently amended) A method of treating an individual who has been identified as having an IgE mediated allergic disease or condition comprising the step of administering to such an individual a prophylactically effective amount of a vaccine of claim 8.

## 11-21 (Canceled)

- 22. (Currently amended) A host cell comprising an isolated nucleic acid molecule that encodes proteins comprising at least one epitope of membrane IgE and at least one nonIgE helper T cell epitope, and being free of epitopes of serum IgE.
- 23 (Currently amended) The host cell of claim 22 wherein said protein is comprises membrane IgE or fragment thereof.
- 24(Currently amended) The host cell of claim 22 wherein said protein is comprises membrane IgE.

## 25. (Canceled)

- 26. (Currently amended) The host cell of claim 25 22 wherein the coding sequence encoding of the at least one non-IgE, helper T cell epitope encodes tetanus toxoid Th epitope.
- 27. (Previously presented) The host cell of claim 22 wherein said nucleic acid molecule is a plasmid.
- 28 (Previously presented) A method of producing a protein comprising at least one membrane IgE and at least one non-IGE helper T cell epitope and being free of epitopes of serum IgE comprising culturing a host cell of claim 22 and isolating said protein expressed thereby.
- 29. (Original) The method of claim 28, wherein the proteins isolated using antibodies that specifically bind to said protein.
- 30-31. (Canceled)
- 32. (New) The vaccine of claim 8 wherein said protein comprises membrane IgE or fragment thereof.
- 33. (New) The vaccine of claim 8 wherein said protein comprises membrane IgE.
- 34. (New) The vaccine of claim 8 further comprising coding sequence encoding at least one non-IgE helper T cell epitope.
- 35. (New) The vaccine of claim 34 wherein the coding sequence encoding the at least one non-IgE, helper T cell epitope encodes tetanus toxoid Th epitope.
- 36. (New) The vaccine of claim 8 wherein said nucleic acid molecule is a plasmid.

- 37. (New) The vaccine of claim 8 wherein said nucleic acid molecule is incorporated in a viral vector or a bacterial cell.
- 38. (New) The method of claim 9 wherein said protein comprises membrane IgE or fragment thereof.
- 39. (New) The method of claim 9 wherein said protein comprises membrane IgE.
- 40. (New) The method of claim 9 further comprising coding sequence encoding at least one non-IgE helper T cell epitope.
- 41. (New) The method of claim 40 wherein the coding sequence encoding the at least one non-IgE, helper T cell epitope encodes tetanus toxoid Th epitope.
- 42. (New) The method of claim 9 wherein said nucleic acid molecule is a plasmid.
- 43. (New) The method of claim 9 wherein said nucleic acid molecule is incorporated in a viral vector or a bacterial cell.
- 44. (New) The method of claim 10 wherein said protein comprises\_membrane IgE or fragment thereof.
- 45. (New) The method of claim 10 wherein said protein comprises\_membrane IgE.
- 46. (New) The method of claim 10 further comprising coding sequence encoding at least one non-IgE helper T cell epitope.

130694-3001 SERIAL NO.: 10/518,701 PATENT FILED: SEPTEMBER 1, 2005

- 47. (New) The method of claim 46 wherein the coding sequence encoding the at least one non-IgE. helper T cell epitope encodes tetanus toxoid Th epitope.
- 48. (New) The method of claim 10 wherein said nucleic acid molecule is a plasmid.
- 49. (New) The method of claim 10 wherein said nucleic acid molecule is incorporated in a viral vector or a bacterial cell.